Facts and reflections on COVID-19 and anti-hypertensives drugs

dc.creatorMarín, Gustavo Horacio
dc.date2020-03-26
dc.date2021-09-06T15:04:26Z
dc.date.accessioned2023-07-15T02:54:54Z
dc.date.available2023-07-15T02:54:54Z
dc.identifierhttp://sedici.unlp.edu.ar/handle/10915/124182
dc.identifierissn:1881-784X
dc.identifierissn:1881-7831
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7463750
dc.descriptionBased on some publications that associate SARS-CoV-2 infection with the use of anti-hypertensive drug groups such as angiotensin-converting-enzyme inhibitors (e.g. enalapril) or angiotensin II receptor blockers (e.g. losartan), many patients from South America, Central America or Spain, have stopped or intend to interrupt their treatments with these drugs. Hence, it may exist ominous consequences due to this drop out. For this reason, it is necessary to quickly warn about this situation and the risks associated with it.
dc.descriptionFacultad de Ciencias Médicas
dc.descriptionConsejo Nacional de Investigaciones Científicas y Técnicas
dc.formatapplication/pdf
dc.format105-106
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rightsCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.subjectCiencias Médicas
dc.subjectACE
dc.subjectATII-RB
dc.subjectAnti-hypertensive drugs
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.titleFacts and reflections on COVID-19 and anti-hypertensives drugs
dc.typeArticulo
dc.typeArticulo


Este ítem pertenece a la siguiente institución